Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells

被引:1
作者
Ji, Bian-Sheng [2 ]
Li, Ming [2 ]
He, Ling [1 ]
机构
[1] China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China
[2] Henan Univ Kaiferng, Key Lab Nat Med & Immune Engn, Nanjing, Peoples R China
来源
PHARMAZIE | 2010年 / 65卷 / 07期
关键词
MULTIDRUG-RESISTANCE; DRUG TRANSPORT; FUNCTIONAL RECONSTITUTION; MEMBRANE GLYCOPROTEIN; VINBLASTINE TRANSPORT; HYDROPHOBIC PEPTIDES; PURIFICATION; HYDROLYSIS;
D O I
10.1691/ph.2009.9803
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
P-Glycoprotein, a 170-180 kDa membrane glycoprotein that mediates multidrug resistance, hydrolyses ATP to efflux a broad spectrum of hydrophobic agents. To observe the interaction of a P-gp reversal agent with P-gp ATPase activity should provide further insights into the mechanisms of P-gp modulator. In this study, we analysed the effect of CJZ3, a lomerizine derivative, on the adenosine triphosphatase (ATPase) activity of human P-glycoprotein. The results showed that the basal P-gp ATPase activity was increased by CJZ3 with half-maximal activity concentration (Km) of 6.8 +/- 1.5 mu M, CJZ3 may interact with P-gp with a higher affinity and exhibit a more potent effect than verapamil (Ver). Kinetic analysis indicated a noncompetitive inhibition of Ver-stimulated P-gp ATPase activity and a competitive inhibition of CJX2-stimulated P-gp ATPase activity by CJZ3, moreover, the effect of CsA on CJZ3-stimulated and Ver-stimulated P-gp ATPase activity showed a non-competitive and a competitive inhibition respectively. CJZ3 and CJX2 can bind P-gp either on overlapping sites or distinct but interacting sites, while CJZ3 and Ver as well as CsA can bind P-gp on separated sites in K562/DOX cells.
引用
收藏
页码:515 / 519
页数:5
相关论文
共 34 条
  • [31] HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway
    Wang, Hong
    Jia, Xiu-Hong
    Chen, Jie-Ru
    Yi, Ying-Jie
    Wang, Jian-Yong
    Li, You-Jie
    Xie, Shu-Yang
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (06) : 2529 - 2537
  • [32] Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway
    Chen, Jie-Ru
    Jia, Xiu-Hong
    Wang, Hong
    Yi, Ying-Jie
    Wang, Jian-Yong
    Li, You-Jie
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (05) : 2063 - 2070
  • [33] Selective inhibition of the effects of phorbol ester on doxorubicin resistance and P-glycoprotein by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) in multidrug-resistant MCF-7/Dox human breast carcinoma cells
    Ahn, CH
    Kong, JY
    Choi, WC
    Hwang, MS
    BIOCHEMICAL PHARMACOLOGY, 1996, 52 (03) : 393 - 399
  • [34] Enhancement of Doxorubicin Cytotoxicity on Human Esophageal Squamous Cell Carcinoma Cells by Indomethacin and 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via Inhibiting P-Glycoprotein Activity
    Yu, Le
    Wu, William Ka Kei
    Li, Zhi Jie
    Liu, Qi Cai
    Li, Hai Tao
    Wu, Ya Chun
    Cho, Chi Hin
    MOLECULAR PHARMACOLOGY, 2009, 75 (06) : 1364 - 1373